Family Counseling for Hepatitis B and Hepatitis C
Tatyana Kushner, Rhoda S. Sperling, Douglas Dieterich – 30 April 2019
Con: Liver Biopsy Remains the Gold Standard to Evaluate Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Daniel Berger, Vishal Desai, Sujit Janardhan – 30 April 2019
Reply
Raymond J. Lynch, Fei Ye, Quanhu Sheng, Zhiguo Zhao, Seth J. Karp – 30 April 2019
Periportal SRY (Sex Determining Region Y)‐Box 9‐Positive Hepatocytes: Progenitors With a Biliary Leaning
Malcolm R. Alison, Wey‐Ran Lin – 29 April 2019
Reply
David Hagerty, Guadalupe Garcia‐Tsao, Jaime Bosch – 29 April 2019
Selective Liver Estrogen Receptor α Modulation Prevents Steatosis, Diabetes, and Obesity Through the Anorectic Growth Differentiation Factor 15 Hepatokine in Mice
Maeva Guillaume, Elodie Riant, Aurélie Fabre, Isabelle Raymond‐Letron, Melissa Buscato, Morgane Davezac, Blandine Tramunt, Alexandra Montagner, Sarra Smati, Rana Zahreddine, Gaëlle Palierne, Marie‐Cécile Valera, Hervé Guillou, Françoise Lenfant, Klaus Unsicker, Raphaël Metivier, Coralie Fontaine, Jean‐François Arnal, Pierre Gourdy – 29 April 2019 – Hepatocyte estrogen receptor α (ERα) was recently recognized as a relevant molecular target for nonalcoholic fatty liver disease (NAFLD) prevention.
Acute Liver Failure During Pirfenidone Treatment Triggered by Co‐Medication With Esomeprazole
Andreas Benesic, Kowcee Jalal, Alexander L. Gerbes – 29 April 2019
Letter to the Editor: Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures
Guandou Yuan, Jiangfa Li, Shuiping Yu, Xiaoping Chen, Songqing He – 29 April 2019
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum
Amanda Cheung, Brent A. Neuschwander‐Tetri, David E. Kleiner, Elmer Schabel, Mary Rinella, Stephen Harrison, Vlad Ratziu, Arun J. Sanyal, Rohit Loomba, Sophie Jeannin Megnien, Richard Torstenson, Veronica Miller, on behalf of the Liver Forum Case Definitions Working Group – 29 April 2019 – Identifying effective therapies for nonalcoholic steatohepatitis (NASH) with fibrosis is a pressing challenge, with 1%‐2% of the population in developed nations at risk of developing NASH cirrhosis and its complications.